Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: ISIS-2503, Isis Pharmaceuticals.

M A Morse1

  • 1Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA. m.morse@cgct.duke.edu

Current Opinion in Molecular Therapeutics
|January 24, 2002
PubMed
Summary
This summary is machine-generated.

ISIS-2503, an antisense oligonucleotide targeting Ha-Ras, is under development for cancer treatment. This therapy is currently in Phase II clinical trials, showing promise for tumors with Ras pathway abnormalities.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial.

ESMO gastrointestinal oncology·2026
Same author

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry.

Journal for immunotherapy of cancer·2019
Same author

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018
Same author

Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.

The British journal of dermatology·2018
Same author

X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.

Cell death & disease·2016

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Ras proteins are key regulators of cell signaling pathways.
  • Abnormalities in Ras function are implicated in the development and progression of many cancers.
  • Antisense oligonucleotide technology offers a targeted approach to modulate gene expression.

Purpose of the Study:

  • To evaluate ISIS-2503, an antisense oligonucleotide, as a potential cancer therapeutic.
  • To investigate the efficacy of inhibiting Ha-Ras expression in tumors with Ras pathway abnormalities.

Main Methods:

  • ISIS-2503 is a 20-mer antisense oligonucleotide designed to inhibit Ha-Ras expression.
  • The drug is currently undergoing Phase II clinical trials.
  • Investigational studies explore its application in various cancer types.

Main Results:

  • ISIS-2503 targets the Ha-Ras gene, a critical component in cancer cell signaling.
  • The drug is being assessed for its therapeutic potential in cancers characterized by Ras pathway dysfunction.
  • Clinical development is ongoing, with the compound in Phase II trials.

Conclusions:

  • ISIS-2503 represents a targeted therapeutic strategy for cancers associated with Ras abnormalities.
  • Further clinical evaluation is necessary to establish its safety and efficacy profile.
  • The development of ISIS-2503 highlights the potential of antisense oligonucleotides in oncology.